Loading
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Regular session
$4.5715
+$0.0115 · +0.25%
Regular session · ET · Market data may be delayed.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Day range
Current $4.5715
52-week range
Current $4.5715
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
37
Expensive
Sentiment
41
Mixed
Risk
54
Elevated Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Day range
Current $4.5715
52-week range
Current $4.5715
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 18.67M USD | 26.39M USD | 34.16M USD | 59.08M USD | 34.75M USD |
| Cost of goods sold | 22.06M USD | — | — | — | — |
| Gross profit | −3.39M USD | 26.39M USD | 34.16M USD | 59.08M USD | 34.75M USD |
| Research and development | 47.75M USD | 55.11M USD | 56.53M USD | 48.36M USD | 39.23M USD |
| Selling, general, and administrative | 29.22M USD | 30.74M USD | 33.31M USD | 24.9M USD | 16.95M USD |
| Operating expenses | 68.13M USD | 100.89M USD | 103.58M USD | 85.73M USD | 70.36M USD |
| Interest income | 2.66M USD | 3.11M USD | 5.06M USD | 587K USD | — |
| Interest expense | — | — | — | — | 7K USD |
| Depreciation and amortization | 21.75M USD | 23.58M USD | 19.5M USD | 18.25M USD | 16.25M USD |
| Operating income | −71.52M USD | −74.5M USD | −69.42M USD | −26.65M USD | −35.61M USD |
| Net income | −64.78M USD | −62.03M USD | −50.62M USD | −22.33M USD | −27.04M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$4.00
12.50% downsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM13.23M0.02%78.56B USD0.19%$277.31-0.14%
Vanguard Morningstar Total Stock Market ETFVTI10.42M0.00%2.3T USD0.03%$378.76-0.60%
Vanguard Extended Market ETFVXF6.12M0.01%95.4B USD0.05%$232.58-0.39%
iShares Biotechnology ETFIBB4.14M0.04%10.4B USD0.44%$199.75-1.77%
Vanguard Russell 2000 ETFVTWO2.77M0.02%18B USD0.06%$112.02-0.17%
Schwab U.S. Small-Cap ETFSCHA2.57M0.01%21.7B USD0.03%$32.5901-0.06%
iShares Micro-Cap ETFIWC1.58M0.12%1.33B USD0.60%$182.47-0.49%
Dimensional - US Small Cap ETFDFAS1.43M0.00%33.66B USD0.31%$78.125+0.26%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
